News

Insurance Companies Must Not Take Shortcuts with Medicare Advantage Record Keeping MarketScale Jan 26, 2023 Insurance Companies Must Not Take Shortcuts with Medicare Advantage Record Keeping – MarketScale Medicare Advantage has allegedly overcharged Medicare by $1,000 per policyholder. Melanie Musson, an insurance expert with ExpertInsuranceReviews.com, says, “Medicare Advantage insurance providers must prepare to justify their […]

  ‘This can only go on so long.’ Patients needing routine care pack MLK emergency department Esmeralda Avendano, right, sits with her son Xavier Gomez, 9, left, inside a tent outside the emergency department at MLK Community Hospital in South Los Angeles. (Francine Orr / Los Angeles Times) BY EMILY ALPERT REYESSTAFF WRITER  Photography by

With the help of a consulting firm, the Providence hospital system trained staff to wring money out of patients, even those eligible for free care.

Politicians on both sides of the aisle spent the midterms telling us that more police and prisons will make us safer. Voters didn’t bite—and perhaps they know better.

Insurers SCAN Group and CareOregon would form HealthRight, covering Medicare and Medicaid enrollees. Two nonprofit health plans focused on government-backed coverage are planning to combine in a deal that aims to create a sizable new player in the rapidly growing business of managed Medicare and Medicaid. SCAN Group, based in Long Beach, Calif., and CareOregon,

CALIFORNIA Plaintiff whose insurer delayed surgery is awarded $14 million over opioid dependency   Health Net was ordered to pay $14.4 million in damages after an L.A. County jury found it had delayed or denied care without proper cause. (Anne Cusack / Los Angeles Times) BY CHRISTIAN MARTINEZSTAFF WRITER  DEC. 15, 2022 5:30 AM PT

As Americans are overwhelmed with medical bills, patient financing is now a multibillion-dollar business, with private equity and big banks lined up to cash in when patients and their families can’t pay for care.

United States. The ALS community rejoiced; the drug’s authorization was described as a “long-sought victory for patients.” But the next day, the price of the medicine was revealed: $158,000 a year. This was far higher than what the Institute for Clinical and Economic Review, an independent nonprofit that analyzes health care costs, had estimated would be a reasonable price, which